Which statement best describes the mortality-reducing pharmacologic therapy for heart failure with reduced ejection fraction?

Which statement best describes the mortality-reducing pharmacologic therapy for heart failure with reduced ejection fraction?

• A. ACE inhibitors or ARBs plus beta-blockers
• B. Calcium channel blockers alone
• C. Diuretics alone
• D. Nitrates alone

Answer: (A)

When treating heart failure with reduced ejection fraction, reducing mortality comes from blocking the hormonal systems that drive disease progression. An ACE inhibitor or an ARB lowers the renin-angiotensin-aldosterone system, which decreases afterload, limits adverse remodeling of the heart, and improves survival. Adding a beta-blocker counteracts the damaging effects of chronic sympathetic activation, slows the heart rate, reduces myocardial oxygen demand, and further protects against remodeling. Together, these two classes address the central neurohormonal mechanisms fueling heart failure and have a proven impact on survival. Diuretics help with symptoms like edema and congestion but don’t confer a mortality benefit. Calcium channel blockers, when used alone in systolic heart failure, can worsen outcomes and are not a mortality-reducing cornerstone. Nitrates alone also do not reduce mortality in this setting. In practice, other therapies (such as mineralocorticoid receptor antagonists or newer agents like ARNIs and SGLT2 inhibitors) can provide additional survival benefits, but the combination of an ACE inhibitor or ARB with a beta-blocker is the foundational mortality-reducing strategy.

When treating heart failure with reduced ejection fraction, reducing mortality comes from blocking the hormonal systems that drive disease progression. An ACE inhibitor or an ARB lowers the renin-angiotensin-aldosterone system, which decreases afterload, limits adverse remodeling of the heart, and improves survival. Adding a beta-blocker counteracts the damaging effects of chronic sympathetic activation, slows the heart rate, reduces myocardial oxygen demand, and further protects against remodeling. Together, these two classes address the central neurohormonal mechanisms fueling heart failure and have a proven impact on survival.

Diuretics help with symptoms like edema and congestion but don’t confer a mortality benefit. Calcium channel blockers, when used alone in systolic heart failure, can worsen outcomes and are not a mortality-reducing cornerstone. Nitrates alone also do not reduce mortality in this setting. In practice, other therapies (such as mineralocorticoid receptor antagonists or newer agents like ARNIs and SGLT2 inhibitors) can provide additional survival benefits, but the combination of an ACE inhibitor or ARB with a beta-blocker is the foundational mortality-reducing strategy.